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history of hypertension or heart failure, weigh less; were less likely to use tobacco, have 
a history of bypass surgery; and were less likely to undergo coronary revascularization. 
(P<O.OOOl all). Increased time to revascularlzation. larger infarction size. and worse ejec- 
tion fraction on discharge were more predictive of stroke in men than in women (table). 
When multivariate analysis was performed of populations individually, these markers 
remained independently predictive in the male. but not female, population. Conclusion: 
Women are at significantly higher risk for in-hospital NHCVA following MI, which is not 
explained by their greater prevalence of other risk factors. 
Variable Males OR [95% 
(7 
Females OR [95% Cl] 
EF < .40 1.58 [1.37-I.831 1.34 [1.18-1.531 
Q waves on admission EKG 1.38[1.14-1.68] 1.04 [O 84-l ,281 
ST elevation > 6 leads 1.51 [1.08-2.111 0.91 [0.60-l ,381 
Door to primary PTCA > 120 minutes 2.71 [1.63-4.511 1.22 [0.78-l ,911 
Door to thrombolyiic > 45 minutes 1.74 [1.17-2.601 1.27 [0.80-2.011 
1146-113 Elevated Troponin I Is an Independent Prognostic 
Marker for Increased Mortality Even in Patients 
Hospitalized With Noncardiac Diagnoses 
Sved W. Bokhari, Curtiss T. Stinis, Jason A. Zell, Cyril Y. Leung, University of Califomia- 
Irvine Medical Center, Orange, CA 
Background: Numerous studies have shown Troponin I (Tnl) to be a valuable predictor 
of prognosis in acute coronary syndrome patients, but none has assessed the clinical 
significance of elevated Troponin I (~0.5 ngimL) in patients hospitalized with non-cardiac 
diagnoses. Methods: In a cross-sectional design, a total of 60 patients, 30 consecutive 
with elevated Troponin I (eTnl) and 30 consecutive with normal Troponin I (nTnl) hospi- 
talized with non-cardiac diagnoses were investigated. Prevalence Rate Ratio (PRR) was 
utilized to analyze all-cause mortality as the prlmaty end-point. Multinomial logistic 
regression analysis was utilized to adjust mortality data for variables that differed signifi- 
cantly between the two groups. Results: The mayor categories of the admitting diag- 
noses were pulmonary (eTnl = 8, nTnl = 9), sepsis (eTnl = 7, nTnl = l), neurological 
(eTnl = 6, nTnl = 9), gastrointestinal (eTnl = 7, nTnl = 6). and others (eTnl =2. nTnl = 5). 
There were no significant differences found between the two groups in terms of their total 
number of cardiac risk factors, previous history of coronary artery disease or coronary 
revascularization, baseline creatinine, hematocrit, cholesterol levels, and use of aspirin, 
beta-blockers, angiotensin converting enzyme Inhibitors, or statins. The eTnl group con- 
sisted of 57% males, compared to 67% males in the nTnl group (p = 0.01). Mean age in 
the eTnl group was 67.8 years compared to 59.8 years in the nTnl group (p = 0.047). Of 
the thirty patients with elevated Trill (mean = 2.10 +/- 0.52 SD), 12 (40%) died during 
index hospitalization as compared to zero deaths reported in patients with normal Tnl 
(mean = 0.04 +/- 0.007 SD), and this dlfference was significant (PRR = 2.7, 95% Cl = 
1.9-3.8, p < 0.0005). Despite differences in age and gender between the two groups, 
adjusted analysis revealed elevated Troponin I to be the only risk factor for mortality (p c 
0.0005 for Tnl; p = 0.9 for gender; p = 0.8 for age). Conclusion: We have shown for the 
first time that the elevated Tropomn I is an Independent prognostic marker for increased 
mortality even in the patients admitted with non-cardiac dlagnoses. There was a trend 
towards more patients with sepsis I” the elevated Troponin I group. 
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1147-92 Initial Results of the Guidelines Applied in Practice for 
improving Quality of Care Patients With Acute 
Myocardial Infarction: The Flint-Saginaw Cooperative 
Initiative of the American College of Cardiology 
Foundation, Greater Flint Health Coalition, and 
Michigan Peer Review Organization 
Rajendra H. Mehta, Cecelia K. Montoye. Jessica Faul, Dorothy Nagle, James Kure, 
Ethira] Raj, Peter Fattal, Mahamadali Amlani, Shire.2 Sherrif, Hameem Changhezi. 
Stephen Skorcz. Patricia Baker, Anthony DeFranco, Kim A. Eaale. on Behalf of ACC 
GAP Steering Committee, University of Michigan, Ann Arbor, Ml 
Background: Since tool use in GAP-Pilot Project resulted in high level of evidence. 
based therapies for pattents with acute myocardial infarctlon (Ml), we decided to test if 
major emphasis on process changes and tool use rather than focusing solely on improv- 
ing key Indicator rates would increase the use of evidence-based therapies. Methods 
The GAP-Flint-Saginaw Ml Initiative was modeled on GAP-Pilot Project in five area hos- 
pitals in Michigan with greater emphasis on tool use and continuous monitoring of tool 
use. This surveillance allowed for early identification of process changes, barriers, and 
reslstance to change. This in turn led to new rapld cycle plans to overcome barriers. Main 
outcome measures were Ml quality indicator use in pre- (l/1/01-6/30/01) and post- (12/ 
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15/01-3/31/02) measurement samples. Results: One or more tools were used in 93% of 
patients (standard orders=82%, critical pathways=79% and discharge document=44%). 
Indicator use is as shown (table). ‘=p<O.O5 compared to baseline. 
Indicators Baseline Remeasureme Remeasurement 
(1x523) nt (rl=499) (With tooI use) 
Withln 24 hours of hospital 
arrival 
Aspirin (%) 
Beta-blockers (%) 
LDL cholesterol measurement 
At discharge 
Asplrin (%) 
Beta-blockers (%) 
ACE inhibitors in patients with 
low LV dysfunction (%) 
Smoking cessation counseling 
(“~) 
Dietary counseling (%) 
Cholesterol lowering agents 
88.9 89.6 92.0 
71.8 71.6 72.0 
82.3 83.6 86.6 
78.8 90.9 93.4 
78.4 90.4 89.3 
69.2 88.8’ 93.7’ 
57.5 72.8’ 84.6’ 
78.1 
76.8 
88.8 95.4’ 
84.1 87.6 
Conclusions These data validate the results of GAP-Pilot Project that quality of MI care 
can be improved through emphasis on guideline-based tool use. Continuous monitoring 
of tool use and identifying/overcoming of barriers, lead to substantially higher tool use 
than observed in initial GAP project. Tool use is associated with higher adherence to key 
indicators, particularly key theraples at discharge. 
1147-93 Predictors of Treatment Delay in Patients With Acute 
Myocardial Infarction Undergoing Primary Angioplasty: 
An Analysis From the CADILLAC Trial 
Mark A. Turco, Martin Fahy, Roxana A. Mehran, Alexandra Lansky, Cindy L. Gr~nes, 
James E. Tcheng, Eulogio Garcia, Giulio Guagliumi, David A. Cox, Thomas D. Stuckey, 
Dawn E. Shaddinger, Gregg W. Stone, Center for Cardiac &Vascular Research and 
Washington Adventist Hospital, Takoma Park, MD, Cardiovascular Research Foundation 
and Lenox Hill Heart and Vascular Center, New York, NY 
Background: Delays in time to angioplasty after hospital arrival in patients (pts) under- 
going primary PCI for AMI have been associated with increased mortality in large data- 
bases. However, the inherent reasons and correlates for delay to angioplasty remain 
poorly understood. 
Methods: We analyzed the baseline demographic, angiographic, and procedure-related 
variables predictive of delays in door-to-balloon time (DB time) in the CADILLAC trial, in 
which 2,082 pts of any age with AMI onset cl2 hours (excluding shock) were randomized 
to PTCA vs stew, with vs without abciximab. 
Results: Median DB time was 120 minutes (interquartile range 90-l 62) for all pts. Statis- 
tically significant clinical predictors of delay > Phrs by univariate analysis included female 
gender (risk ratio 1.13, pcO.OOOl), circumflex infarction (RR 1.54, p<O.OOOl), insulin 
dependent diabetes (RR 2.22, p=O.O02), prior CABG (RR 3.28, p=O.O2), non-ST-eleva- 
tion Ml (RR 4.35. pcO.OOOl), 3 vessel disease (RR 1.30, p=O.O2), and delayed time to ER 
arrival (p=O.O003). Anglographic predictors of delay included pre-procedure TIMI- flow, 
small reference vessel diameter and larger initial MLD (all p<O.OOOl). Multtvariate predic- 
tors of delay using stepwise logistic regression Included non-LAD infarction (p=O.O4), 
female gender (p=O.O004), 3-vessel disease (p=O.O2), small reference vessel diameter 
(p<.OOOl), and larger initial MLD (p<O.OOOl). 
Conclusion: The time from hospital presentation to angioplasty IS >2hrs in 50% of pts 
with AMI undergoing contemporary interventional management. Predictors of delay to 
treatment after hospital arrival may be explained by atypical symptoms or indeterminate 
ECGs (female gender or LCX Ml), and less severe symptoms (smaller infarct vessel or 
patency of infarct vessel due to larger MLD). These data emphasize the need for aware- 
ness and expedited reperfusion pathways for patients at highest risk for delays to PCI. 
1147-94 Beneficial Effects of Direct Call to Emergency Medical 
Services on Time Delays and Management of Patients 
With Acute Myocardial Infarction: Real World Data From 
RICO Database 
Jean-Claude Beer, Gilles Dentan. Luc Janin-Manificat, Marianne Zeller, Yves Laurent, 
lsabelle Lhuillier, Jacques Ravisy Yves Cottin Jean-Eric Wolf, CHU Dijon, Dljon. France 2-1 
Background. Delayed access to medical care in patients with acute myocardial infarc- 
tion (AMI) increases myocardial damage. Only few studies have analysed the influence 
of direct call to emergency medical services (EMS) in patients with AMI. From the 
regional observatory of Ml (RICO) data base, we report the acute management in 
patients calling either EMS or other medical contact (OMC) as first medical seek after 
symptoms onset of Ml. Methods Data were prospectively collected from January to 
October 2001, in the 6 medical units in charge of Ml in the region of Cote d‘Or. Among 
the 322 patients included, only 57 (18%) directly called EMS after symptoms onset 
(group EMS) and 265 (82%) called another medical contact (group OMC). Results The 
baseline characteristics including age and risk factors were similar among the 2 groups 
of patients. Moreover, cardiovascular history was the same between the two groups, 
except for history of MI (21 % in EMS group vs 11 % I” OMC group, ~~0.05). The median 
tbmes from symptoms onset to first medical Intervention (48 vs 105 min, ~~0.02) and from 
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first medlcal intervention to hospital admission (60 vs 103 min, p<O.O2) were markedly 
shorter in EMS group. We also observed a significant increase in reperfusion therapy at 
the acute phase tn EMS group compared to OMC group (respectively 70 % vs 48 %, 
p<O.O03), mainly due to a higher rate of primary angioplasty (respectively 33 % vs 20 %, 
~~0.04). Conclusion. Our study in real world collecting data from a French regional pop- 
ulation demonstrated that only a small rate of patients use the direct call tc EMS at symp- 
toms onset of MI. This study also documents the beneficial effect of a direct call to EMS 
by reducing the pre-hospital delays and by Increasing the rate of early revascularisation. 
1147-95 Glycoprotein llblllla Inhibitors Are Underutilized Among 
Patients Who Undergo Cardiac Catheterization 
Following Acute Myocardial Infarction: Observations 
From the NRMI-4 
John G. Canto, Eric Peterson, Charles Pollack, Lori Parsons, Nathan Ft. Every, Willlam J 
Rogers, Catarina I, Kiefe. Kathee Litrell, Hal V. Barron, for the NRMI Investigators, The 
University of Alabama at Birmingham, Birmingham, AL, Duke Clinical Research Institute. 
Durham, NC 
tion) and in 2001 (after last pathway’s’ revision) were rewewed. A STEMI was diagnosed 
at ED in 52015,066 (10.3%) chest pain pts in 1997, and in 452/4,843 (9.3%) chest pain 
pts in 2001. Pts were managed according to the ED cardiologist’s decisions I” 1997, 
whereas entered the pathway for STEMI in 2001, with pre-defined criteria for diagnosis, 
thrombolysis, percutaneous coronary intervention (PCI) and admission to CCU. 
Results: Comparison of treatment modalities disclosed that mwe pts were given throm- 
bolysis in 1997 (49% vs 16%. p<O.O5). whereas in 2001 more pts were sent to PCI (63% 
vs 1 l%, ~~0.05). In 2001, also. pts received more often aspirin (90% vs 61%. ~~0.05) 
and i.v. beta-blocker (60% vs 35%. ~~0.05) soon after arrival at ED. Comparison 
between 1997 and 2001 revealed similar admission rates to CCU (69% vs 78%, NS) or 
cardiac wards (19% vs IO%, NS). Conversely, with respect to 1997, pts hospitakzed in 
2001 had shorier length-of-stay (12+5 vs 18s days, pcO.05) as well as lower major 
adverse coronary events (21% vs 30%, ~~0.05) and lower all-cause In-hospital moriality 
(12% vs 20%, p<O.O5). The quality of care indicators improved with time. as door-to-ECG 
interval (lM_6 vs 1969 min. p<O.O5), door-to-needle time (Z&l0 vs 35110 min. ~~0.05). 
and door-to-balloon Interval (70215 vs 99&?0 min, ~~0.05) were shorter in 2001 than I” 
1997. 
Background. Glycoproteln Ilb-llla Inhibitors (GPls) have been shown to improve the out- 
comes of patients with acute coronary syndromes. Recent reports have suggested that 
many Ml patients who may be eligible for GPls still do not receive these treatments. 
Methods. We examined the prevalence of GPI use in the NRMI 4 (Jul 2000 - Apr 2001) 
and created a predictive model to bener ascertain the factors associated with GPI use. In 
order to minimize selection bias and confounding. we selected patients who received 
cardiac catheterization and presented at fully interventional capable hospitals. Patients 
who had contralndications to GPI and who were transferred-out to another hospital were 
excluded from this study. Results. 
Conclusions: A critical pathway for STEMI at ED increases the use of evidence-based 
treatment strategies and improves outcome and quality of care of pts presenting to an 
ED because of acute chest pain. 
1147-97 Use of Reperfusion Therapy in Patients Presenting With 
ST Elevation Myocardial Infarction: Findings From The 
TETAMI Study and TETAMI Registry (The Safety and 
Efficacy of Subcutaneous Enoxaparin Versus 
Intravenous Unfractionated Heparin and of Tirofiban 
Versus Placebo in the Treatment of Acute Myocardial 
Infarction) 
Utilization of GP Ilb-llla Inhibitors (GPls) after MI, N = 24,438 
GPI No GPI 
CATH: N = 24,438 
Elective PCI. N = 6,086 
Primary PCI: N = 1,314 
43.4% 56.6% 
77.4% 22.6% 
86.8% 13.2% 
MY analysis of the factors associated with GPI use 
Non-Whites 
Women 
Age 10 years 
History CHF 
Prior MI 
Medicare (YS FFS) 
COPD 
Smoker 
West (vs Midwest) 
South (vs Midwest) 
Anterior Ml 
Prior CABG 
Prior PTCA 
LBBB 
Chest pain 
Odds Ratlo P value 
0.80 < 0.001 
0.90 0.001 
0.92 < 0.001 
0.83 0.002 
0.87 < 0.001 
0.88 0.002 
0.90 0.03 
1.11 0.003 
1.17 < 0.001 
1.17 < 0.001 
1.21 < 0.001 
1.16 < 0.001 
1.31 < 0.001 
1.59 < 0.001 
1.72 < 0.001 
OR < 1 .O associated with less use; OR > 1 .O more use 
Conclusion. Less than half of oatients with Ml who mav be elioible for GPls act&Iv 
received these therapies. M&ties. women and increasing age were important factors 
associated with less use, though chest pain on initial presentation and prior coronary 
revascularization were associated with more use. 
1147-96 Critical Pathways in the Emergency Department Have 
Improved Treatment Modalities and Outcome for 
Patients With ST Elevation Myocardial Infarction 
Francesco Pelliccla, Domenico Cartoni, Paolo Salvini, Sandra Petrolati. Alberta Clfarelli, 
Francesco Pozzar, Pietro Tanzi. San Camille Hospital, Rome, Italy 
Background: The use of protocols for pts with ST elevation myocardial infarction 
(STEMI) is growing, but no definite conclusion regarding the value of critlcal pathways 
has been drawn. Aim of this study was to investigate the impact of a critical pathway on 
processes of care and outcome for pts accessing the emergency department (ED) 
because of a possiale STEMI. 
Methods: Critical pathways for management of acute chest paIn and STEMI at our ED 
were developed in 1998 and revised every year. Accordingly, the records of all pts who 
were referred because of chest pain to the ED in 1997 (before pathways’ implementa- 
Gian France Gensini, Marc Cohen, Frans Maritz, Enrique P. Gurflnkel, Kurt Huber, Ari 
Timerman, Maria Krzeminska-Pakula. Nicolas Danchin, Harvey D. White, Luc Vittori, 
Clinical Medica Generale e Cardiologia, Florence, Italy 
Early treatment with lytics or primary PCI reduces the mortality rate of STEMI patients. 
Pts presenting >12 h are generally considered to be ineligible for repelfusion therapy, 
and there are currently no specific treatment recommendations. 
Methods: Patients with STEMI ~24 h who are ineligible for acute reperfusion, have no 
cardiogenic shock and with no revascularization scheduled within 48 h were included in 
the TETAMI study and randomized to 1 of 4 antithrombotic regimens involving enox- 
aparin or UFH in combination with tirofiban or placebo for 2-8 days. A concurrent registry 
tracked STEMI patients reperfused ~12 h and non-repedused patients presenting <24 h 
and not enrolled in TETAMI. We compared the demographics and clinical outcomes of 
1397 pts ineligible for acute reperiusion with 1146 pts eligible for reperfusion. 
Results: Outcomes are presented below. The major reason for not using reperfusion 
therapy was late presentation. Repeiiused registry patients were younger: aged 61, com- 
pared with 63 and 67 years for TETAMI patients and non-reperfused registry patients; 
more likely to be male (78%. 73% and 63%, respectively), and had persistent ST eleva- 
tion as opposed to LBBB or Q waves. Reperfused registry patients had better outcomes 
even after adjusting for admisslon Killip class. TETAMI patients had better outcomes 
than non-reperfused registry patients. 
Conclusion: These data highlight the need for new therapeutic strategies for this high 
risk patient cohort. 
1147-98 International Patterns in the Care of Acute Myocardial 
Infarction Patients in the Occluded Artery Trial (OAT): 
Characteristics of 1,835 Screened Patients 
Michael Raaosta Aldo P. Maggioni, Lampros K. Michalis, Irene tang, Antonio C. 
Carvalho, Krystyna Loboz-Grudzlen, Gerry Devlin, Gilmar Reis, Peter Merciar, Sandra 
Forman, Gervasio A. Lamas, Judith S. Hochman, on behalf of OAT Investigators. 
Charlottesville. VA 
Background Up to l/3 of stable post-MI patlents have an occluded infarct-related artery 
(IRA). OAT is an international, randomized trial designed to determlne If benefit exists in 
opening the occluded IRA 3-28 days post-MI in asymptomatic. high-risk patients. As of 91 
l/02, 911 patients were randomized. The purpose of this interim analysis is to define 
characteristics that correlate with practice differences in the care of acute Ml I” OAT sites 
in the US, Canada and other countries. A criterion for SelectIon of an OAT site was the 
availability of an experienced PCI operator who met rigorous standards. 
Methodology In order to define the population of MI patients from which OAT patients 
